Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07099131 · ClinicalTrials.gov registry record · Early Phase 1
Effective Interventions to Overcome Severe Gag Reflex
A Early Phase 1 study, sponsored by Tufts University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
NCT07099131: Clinical Trial Early Phase 1 study, sponsored by Tufts University.
NCT07099131 is a Early Phase 1 study that has not yet begun recruiting, run by Tufts University. The registered enrollment target is 45 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07099131, a Early Phase 1 study, has not yet begun recruiting, sponsored by Tufts University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of various techniques in alleviating gag reflex following gag reflex stimulation. Primary aim: To compare if there is any reduction in gag reflex from each of the following interventions * Acupuncture (CV-24) * Tape * Anesthetic spray Secondary aim: to compare the degree of gag reduction
Primary Outcome
Change in Gag Reflex Severity Index (GSI) Score From Baseline to Post-Intervention * Acupuncture (CV-24) * Tape * Anesthetic spray Gag reflex severity will be assessed by clinicians using the Gagging Severity Index (GSI), based on definitions set by Dickinson and Fiske. GSI will first be recorded after initial gag stimulation with a cotton swab. Following randomization to one of three interventions (acupuncture, anesthetic spray, or masking tape), GSI will be recorded again. The change in GSI
Interventions
- DEVICE Acupuncture
- DRUG Anesthetic spray
- GENETIC Masking Tape
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-12-07 |
| Est. Completion | 2028-12-07 |
| Phase | Early Phase 1 |
What is known before NCT07099131 opens enrollment
NCT07099131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 3 interventions - of which Acupuncture is the first listed.
NCT07099131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07099131 about?
NCT07099131 is a clinical study titled "Effective Interventions to Overcome Severe Gag Reflex". The purpose of this study is to evaluate the use of various techniques in alleviating gag reflex following gag reflex stimulation. Primary aim: To compare if there is any reduction in gag reflex from each of the following interventions * Acupuncture (CV-24) * Tape * Anesthetic spray Secondary aim:...
What is the current status of trial NCT07099131?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2025-12-07. Estimated completion is 2028-12-07.
What interventions are being tested in trial NCT07099131?
The interventions under investigation include: Acupuncture (DEVICE), Anesthetic spray (DRUG), Masking Tape (GENETIC).
Who is sponsoring clinical trial NCT07099131?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07099131's enrollment target sits among peer trials
45 575th of 2000 higher than 1,412 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI